Related Experiment Videos
[Adverse effects of zopiclone]
1Psykiatrisk Klinikk, Vinderen.
Summary
Zopiclone, a cyclopyrrolone hypnotic, shows market growth but lacks adverse effect documentation. It shares similarities with benzodiazepines, with potential for psychomotor inhibition and addiction.
Area of Science:
- Pharmacology
- Clinical Pharmacy
Context:
- Zopiclone (Imovane), a cyclopyrrolone, was introduced in Norway in 1994 and captured 26% of the hypnotic market by 1996.
- Comparative research on zopiclone's adverse effects is limited, with much existing data focusing on triazolam, withdrawn in 1991.
Purpose:
- To review the available literature on zopiclone's adverse effects and compare its profile to benzodiazepine hypnotics.
- To assess zopiclone's impact on psychomotor function and potential for addiction compared to other hypnotics.
Summary:
- Zopiclone exhibits significant similarities to benzodiazepine hypnotics.
- While zopiclone may cause less psychomotor inhibition than flunitrazepam and less subjective hangover than nitrazepam, it can still impair psychomotor function and potentially has a greater addictive potential than nitrazepam.
Impact:
- Highlights a need for more comprehensive documentation of zopiclone's adverse effects.
- Provides a comparative overview of zopiclone's effects relative to other hypnotics, informing clinical practice and patient safety.